USP Pharmaceutical Analytical Impurities

(2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid)

(methyl (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylates)

(2,2'-((hexane-1,6-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) iodides)

(25 mg

(N-Methyl-4-[4-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxamide; N-Methyl-4-{4-[3-(3-trifluoromethylphenyl)ureido]phenoxy}picolinamide)

(25 mg

(4-(4-formamidophenoxy)-N-methylpicolinamide)

(4-(2-(Methylamino)ethyl)benzene-1,2-diol hydroiodide)

(Ethyl (S)-3-(3,4-dihydroxyphenyl)-2-hydrazineyyl-2-methylpropanoate)

((1R,2R)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-(3-methoxy-3-oxopropyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline-2-iumbenzenesulfonate)

((E)-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride)

(Lithium(2S,3R)-2-ethyl-4-hydroxy-3-((1-methyl-1H-imidazol-5-yl)methyl)butanoate)

(Lithium (2R,3R)-2-ethyl-4-hydroxy-3-((1-methyl-1H-imidazol-5-yl)methyl)butanoate)

(4-amino-3-chloro-N-(5-methylisoxazol-3-yl)benzenesulfonamide)

(2-amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-4-ol)

(2-[(2-Ethoxy-1-naphthamido)methyl]-5,5-dimethylthiazolidine-4-carboxylic acid)

((E)-N-methyl-N-((4-methylnaphthalen-1-yl)methyl)-3-phenylprop-2-en-1-amine hydrochloride)

((Z)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride)

(4,4'-[carbonylbis(azanediyl-4,1-phenyleneoxy)]bis(N-methylpyridine-2-carboxamide);N,N'-Bis{4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl}urea)

(Carbamic acid, [4-chloro-3-(trifluoromethyl)phenyl]-, ethyl ester)

(4-(Pyridin-2-yl)benzaldehyde)